Importer of Controlled Substances; Notice of Registration, 43455 [05-14825]
Download as PDF
<![CDATA[
43455
Federal Register / Vol. 70, No. 143 / Wednesday, July 27, 2005 / Notices
manufacture the listed basic class of
controlled substance is consistent with
the public interest at this time. DEA has
investigated Boehringer Ingelheim
Chemical Inc. to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: July 19, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–14831 Filed 7–26–05; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration
By Notice dated April 11, 2005 and
published in the Federal Register on
April 20, 2005 (70 FR 20600), Clinical
Trial Services (US), Inc., 2661 Audubon
Road, Audubon, Pennsylvania 19403,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as an importer of
Fentanyl (9801), a basic class of
controlled substance listed in Schedule
II.
The company plans to import small
quantities of the listed controlled
substance in dosage form to conduct
clinical trials.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a)
and determined that the registration of
Clinical Trial Services (US), Inc. to
import the basic class of controlled
substance is consistent with the public
interest and with United States
obligations under international treaties,
conventions, or protocols in effect on
May 1, 1971, at this time. DEA has
investigated Clinical Trial Services (US),
Inc. to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
VerDate jul<14>2003
19:40 Jul 26, 2005
Jkt 205001
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic class of controlled substance
listed.
Dated: July 19, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–14825 Filed 7–26–05; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated February 23, 2005,
and published in the Federal Register
on March 4, 2005, (70 FR 10679), JFC
Technologies, LLC, 100 West Main
Street, Bound Brook, New Jersey 08805,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic class of
controlled substances listed in Schedule
II:
Drug
Schedule
Diphenoxylate (9170) ...................
Hydrocodone (9193) .....................
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of JFC
Technologies, LLC to manufacture the
listed basic class of controlled
substances is consistent with the public
interest at this time. DEA has
investigated JFC Technologies, LLC to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic class of controlled substances
listed.
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
Dated: July 19, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–14836 Filed 7–26–05; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By notice dated February 23, 2005,
and published in the Federal Register
on March 4, 2005 (70 FR 10680), Lin Zhi
International Inc., 687 North Pastoria
Avenue, Sunnyvale, California 94085
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic class of
controlled substances listed in Schedule
II:
Drug
Oxycodone (9143) ........................
Hydrocodone (9193) .....................
Schedule
II
II
The company plans to manufacture
the listed controlled substances in bulk
for use in analysis and drug test
standards.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of Lin
Zhi International Inc. to manufacture
the listed basic class of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Lin Zhi International Inc. to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic class of controlled substances
listed.
Dated: July 19, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–14828 Filed 7–26–05; 8:45 am]
BILLING CODE 4410–09–P
E:\FR\FM\27JYN1.SGM
27JYN1
]]>Agencies
[Federal Register Volume 70, Number 143 (Wednesday, July 27, 2005)]
[Notices]
[Page 43455]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-14825]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Registration
By Notice dated April 11, 2005 and published in the Federal
Register on April 20, 2005 (70 FR 20600), Clinical Trial Services (US),
Inc., 2661 Audubon Road, Audubon, Pennsylvania 19403, made application
by renewal to the Drug Enforcement Administration (DEA) to be
registered as an importer of Fentanyl (9801), a basic class of
controlled substance listed in Schedule II.
The company plans to import small quantities of the listed
controlled substance in dosage form to conduct clinical trials.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and 952(a) and determined that the
registration of Clinical Trial Services (US), Inc. to import the basic
class of controlled substance is consistent with the public interest
and with United States obligations under international treaties,
conventions, or protocols in effect on May 1, 1971, at this time. DEA
has investigated Clinical Trial Services (US), Inc. to ensure that the
company's registration is consistent with the public interest. The
investigation has included inspection and testing of the company's
physical security systems, verification of the company's compliance
with state and local laws, and a review of the company's background and
history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in
accordance with 21 CFR 1301.34, the above named company is granted
registration as an importer of the basic class of controlled substance
listed.
Dated: July 19, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 05-14825 Filed 7-26-05; 8:45 am]
BILLING CODE 4410-09-P
